Bioventus (BVS) Gross Margin (2020 - 2026)

Bioventus (BVS) has reported Gross Margin for 7 consecutive years, with 68.97% the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Gross Margin fell 17.0% year-over-year to 68.97%; the trailing twelve-month figure through Jun 2026 stood at 68.65% (up 105.0% YoY), and the FY2025 full-year result was 68.33%, up 61.0% from the prior year.
• Gross Margin held at 68.97% in Q2 2026 per BVS's latest filing, from 68.72% in the prior quarter.
• Across five years, Gross Margin topped out at 69.14% in Q2 2025 and bottomed at 58.96% in Q4 2022.
• Historically, Gross Margin has averaged 66.44% across 5 years, with a median of 67.18% in 2024.
• The sharpest annual moves came in 2022 and 2024: Gross Margin tumbled 834 bps in 2022, then jumped 618 bps in 2024.
• Over 5 years, Gross Margin stood at 58.96% in 2022, then climbed by 8 bps to 63.73% in 2023, then advanced by 5 bps to 66.82% in 2024, then rose by 3 bps to 68.89% in 2025, then gained by 0 bps to 68.97% in 2026.
• According to Business Quant data, Gross Margin over the past three periods registered 68.97%, 68.72%, and 68.89% for Q2 2026, Q1 2026, and Q4 2025 respectively.